Clinical Trial Update: Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining sympathoinhibition as a preferred second-line treatment for obesity-related hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Obesity

Snippet

Sponsor: Royal Perth Hospital | Conditions: Obesity, Hypertension | Phase 4 | Status: UNKNOWN